SCHEMBL6413690

SCHEMBL6413690

COc1cccc(C=NNc2nc3nonc3nc2NCc2ccccc2)c1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.51
KDM4E B2RXH2 10/20 0.51
KMT2A Q03164 10/20 0.51
HTT P42858 8/20 0.51
MEN1 O00255 7/20 0.51
SMN1; SMN2 Q16637 6/20 0.51
LMNA P02545 4/20 0.51
MITF O75030 2/20 0.51
MAPK1 P28482 1/20 0.51
TDP1 Q9NUW8 4/20 0.50
L3MBTL1 Q9Y468 4/20 0.50
KLF5 Q13887 3/20 0.50
PKM P14618 2/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
ADORA2A P29274 1/20 0.50
GAA P10253 4/20 0.48
KDM4C Q9H3R0 1/20 0.48
NPC1 O15118 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6413685 1.00 MAPT (0.51) MAPTKDM4EKMT2AHTTMEN1
SCHEMBL6417306 0.87 ERN1 (0.44) MAPTKDM4EKMT2AHTTMEN1
SCHEMBL6419561 0.85 MAPT (0.53) MAPTKDM4EKMT2AHTTMEN1
SCHEMBL6414665 0.84 DDX3X (0.53) MAPTKDM4EKMT2AHTTMEN1
SCHEMBL6432987 0.82 ADORA2A (0.51) MAPTKDM4EKMT2AHTTMEN1
SCHEMBL6433398 0.82 ADORA2A (0.51) MAPTKDM4EKMT2AHTTMEN1
SCHEMBL6433407 0.82 ADORA2A (0.51) MAPTKDM4EKMT2AHTTMEN1
SCHEMBL6416976 0.82 ADORA2A (0.51) MAPTKDM4EKMT2AHTTMEN1
SCHEMBL6439515 0.80 MAPT (0.51) MAPTKDM4EKMT2AHTTMEN1
SCHEMBL6436226 0.80 MAPT (0.51) MAPTKDM4EKMT2AHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885KDM4E 3277/4885KMT2A 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.